FutureMeds Joins IQVIA's Prime Site Network, Strengthening Clinical Research Across Europe

FutureMeds, a leading European clinical research site network, has officially joined IQVIA’s Prime Site Network, marking a significant milestone in its mission to transform trial efficiency and patient experience across Europe.

FutureMeds, a dedicated clinical research network operating across six European countries, with a DCT Service available in 18, has been awarded Prime Site designation by IQVIA, a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry.

"We are honoured to be recognized by IQVIA as their strategic partner in a mission of transforming clinical research into a compassionate, integrated part of healthcare.The invitation to become a Prime Site Network member is a recognition of FutureMeds' unique market position in Europe, which combines a dedicated research site network with decentralised trial solutions. We see it as an opportunity to offer even more opportunities to patients across Europe to participate in clinical research."

— Dr Radoslaw Janiak, Chief Executive Officer of FutureMeds

The IQVIA Prime Site program provides long-term strategic collaboration with sites characterised by clinical and technological excellence. Clinical trials that take place in the Prime Site Network adhere to the highest international ethical and regulatory standards.

FutureMeds has worked closely with IQVIA since 2022 to facilitate more equitable access to new therapies and improve the quality of life and safety of patients.

In the last 2 years, FutureMeds has collaborated with IQVIA across six European countries: Poland, United Kingdom, Germany, Bulgaria, Ukraine, and Spain. This collaboration has led to doubling the number of FutureMeds sites in IQVIA studies and an 8-fold increase in patient recruitment across over 15 therapy areas.

"Achieving this designation highlights our commitment to delivering excellence in clinical trials across Europe. Excited to continue making strides together and driving innovation in healthcare," added Cameron Glen, Global VP of Business Development at FutureMeds.

This partnership between FutureMeds and IQVIA represents a significant step forward in advancing clinical research and improving healthcare outcomes across Europe.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using artificial intelligence ("AI") responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 89,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.